No Data
No Data
Goli Pharmaceutical-B (01672.HK): 23 years of steady growth, focusing on differentiated innovation pipelines, deepening R&D in the MASH field
Incident: Goli Pharmaceuticals Announces 2023 Results: Revenue Up 4.6% Year Over Year, Loss Narrowed 54% Year On Year; Significant Progress Has Been Made in Multiple R&D Pipelines: ASC41-NASH, ASC40-NASC40-LIT
Goli Pharmaceutical-B (1672.HK): Innovative drug development has achieved excellent results and sufficient cash reserves
Event: The company announced its 2023 results. Revenue for 2023 increased 4.6% to RMB 56.6 million. Revenue from ritonavir products increased by about 49.4 million yuan, and losses from 3.15 in '22
Goli Pharmaceutical-B (01672) announced its 2023 annual results, with revenue of about 56.6 million yuan, an increase of 4.6% over the previous year
Goli Pharmaceutical-B (01672) announced the results for the year ended December 31, 2023. The Group's revenue increased from 2...
Goli Pharmaceutical-B (01672.HK) annual loss reduced to 145 million yuan
Gelonghui, March 25 | Goli Pharmaceutical-B (01672.HK) announced that for the year ended December 31, 2023, the company's revenue increased 4.6% from approximately RMB 54.1 million in the previous year to approximately RMB 56.6 million. The Group's total revenue (including revenue and other revenue and revenue) increased by 45.2% from approximately RMB 166.1 million in the previous year to approximately RMB 241.2 million. The Group's loss for the year decreased from RMB 314.8 million in the previous year to RMB 144.7 million in the same year, mainly due to (i) the increase in product sales revenue
ASCLETIS-B: ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
No Data